Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CorMedix Provides Update On CE Marking Process For Neutrolin

RELATED NEWS
Trade CRMD now with 

CorMedix Inc. (CRMD: Quote) on Thursday announced the receipt of a request for additional information and data, including six month stability data on the third and final test batch from TUV-SUD and MEB-Netherlands on the CE Mark application for Neutrolin in the EU.

Upon delivery of the requested information, the company believes that Neutrolin will enter a third and final round of review to finalize the CE Mark.

CorMedix anticipates providing such additional information and data in late third quarter or early fourth quarter of 2012.

As a result, CorMedix now expects a final review and determination regarding its CE Mark application by the end of 2012.

CorMedix said it is currently in the final stages of completing its commercialization plan and is in talks with several potential partners regarding the launch of Neutrolin in Europe.

Based on the status of such talks CorMedix continues to target a commercial launch for fourth quarter of 2012 or first quarter of 2013.

Click here to receive FREE breaking news email alerts for CorMedix Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.